TABLE 3.
Clinical characteristics of lymphoma patients with germline pathogenic variants
| Lymphoma patients (n = 1,982) | p value | ||
|---|---|---|---|
| Pathogenic variant carriers (n = 31) | Pathogenic variant non‐carriers (n = 1,951) | ||
| Age at diagnosis, median (interquartile range) a | 61 (54; 73) | 62 (53; 70) | 0.721 |
| Sex (%) b | |||
| Male | 22 (71.0) | 1,105 (56.6) | 0.143 |
| Female | 9 (29.0) | 846 (43.4) | |
| Family history of cancer (%) | |||
| Lymphoma | 0 (0.0) | 54 (2.8) | 1.000 |
| Leukemia | 0 (0.0) | 36 (1.9) | 1.000 |
| Breast cancer | 7 (22.6) | 95 (4.9) | 7.00 × 10−4 |
| Ovarian cancer | 2 (6.5) | 10 (0.5) | 1.42 × 10−2 |
| Pancreatic cancer | 0 (0.0) | 67 (3.4) | 0.624 |
| Prostate cancer | 1 (3.2) | 57 (2.9) | 0.605 |
| Colon cancer | 1 (3.2) | 178 (9.1) | 0.356 |
| Lung cancer | 3 (9.7) | 168 (8.6) | 0.746 |
| Gastric cancer | 4 (12.9) | 413 (21.2) | 0.374 |
| Subtype of lymphoma (%) b | |||
| Diffuse large B‐cell lymphoma | 14 (45.2) | 777 (39.8) | 7.10 × 10−2 |
| Follicular lymphoma | 4 (12.9) | 329 (16.9) | |
| Hodgkin lymphoma | 1 (3.2) | 153 (7.8) | |
| MALT lymphoma | 2 (6.5) | 136 (7.0) | |
| Mantle cell lymphoma | 4 (12.9) | 40 (2.1) | |
| Peripheral T‐cell lymphoma | 0 (0.0) | 30 (1.5) | |
| Angioimmunoblastic T‐cell lymphoma | 0 (0.0) | 24 (1.2) | |
| Burkitt lymphoma | 0 (0.0) | 14 (0.7) | |
| Extra nodal T/NK‐cell lymphoma | 0 (0.0) | 12 (0.6) | |
| Anaplastic large cell lymphoma | 0 (0.0) | 13 (0.7) | |
| Adult T‐cell lymphoma | 0 (0.0) | 12 (0.6) | |
| B‐cell lymphoma NOS | 1 (3.2) | 104 (5.3) | |
| T/NK‐cell lymphoma NOS | 1 (3.2) | 18 (0.9) | |
| Other lymphoma | 0 (0.0) | 71 (3.64) | |
| Unknown | 4 (12.9) | 218 (11.2) | |
Note: Other evaluations were performed using Fisher's exact test.
Pathogenic variant carriers were defined in ATM, BRCA1, BRCA2, or TP53.
MALT lymphoma, extranodal marginal zone lymphoma of mucosa‐associated lymphoid tissue; NOS, not otherwise specified.
a
Evaluated by Mann–Whitney U‐test.
b
Evaluated using the χ2‐test.